Please ensure Javascript is enabled for purposes of website accessibility

Why Exact Sciences Corporation Stock Gained Nearly 14% in June

By George Budwell - Updated Jul 8, 2019 at 10:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's recent momentum is showing no signs of cooling off, despite its jaw-dropping valuation.

What happened

Shares of the cancer diagnostic specialist Exact Sciences Corporation (EXAS 0.83%) gained 13.9% over the course of June, according to data from S&P Global Market Intelligence. What was the catalyst?

Exact's shares have been on an absolute tear this entire year for a few good reasons. First off, sales of the company's novel colon cancer test Cologuard have been growing at a rapid clip -- especially since the biotech formed a marketing and promotional partnership with Pfizer (PFE 3.77%) late last year

Image of a human colon bisected to show an reddish area exhibiting cancerous cells set against a bluish background.

Image source: Getty Images.

Cologuard's heady sales trajectory, in turn, has been fueling speculation on Wall Street that Exact might be a top takeover target. Last but certainly not least, the company has also been striving to build, with its partner the Mayo Clinic, a broad liquid biopsy franchise that could generate tens of billions in sales over the next decade.     

So what

While Cologuard's sales are forecast to top $1 billion as soon as next year, a good chunk of the company's future top-line growth appears to be priced in at this point. Exact's shares, after all, are now trading at an astronomical 15 times next year's projected sales.

Now, the biotech's sky-high valuation could fall dramatically in the years ahead if Exact can successfully tack on additional indications to its unique cancer diagnostic franchise. But it's also important to bear in mind that there are other players attempting to break into this high-value market right now. Thus Exact may not be able to hold on to its virtual monopoly for the entirety of the next decade, which seems to be the prevailing assumption among investors in light of the biotech's present valuation.  

Now what

Exact's immense valuation probably also means that a buyout is off the table. And Pfizer, Exact's marketing partner and often-rumored suitor, just plopped down $10.6 billion to gobble up Array BioPharma -- so that door appears to be closed for the time being. 

Although Exact's core business is humming along like clockwork, investors may want to consider taking some profits after this monstrous run. That's not to say that Exact's stock is destined to cool off in the near term, but it does appear to be hitting rarefied air at this point -- especially now that a buyout no longer appears to be in the cards. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exact Sciences Corporation Stock Quote
Exact Sciences Corporation
$42.71 (0.83%) $0.35
Pfizer Inc. Stock Quote
Pfizer Inc.
$50.11 (3.77%) $1.82
Array Technologies, Inc. Stock Quote
Array Technologies, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.